Breakthrough could lead to new antimicrobial drugs

Jun 10, 2009

After 25 years of painstaking studies - led by Professor Ian Booth at the University of Aberdeen and Dr Tarmo Roosild at Nevada Cancer Institute in Las Vegas - scientists have figured out the mechanics of 'channels' in bacteria which stay shut if all is normal and are triggered to open if they need to mount a defence.

The breakthrough finding published in the journal Structure paves the way for the development of new methods for tackling E.coli, salmonella and brucella infections; as well as the bacteria Pseudomonas, which often colonise the lungs of cystic fibrosis patients and also cause infection in those whose immune systems are compromised.

Professor Booth collaborated with Nevada Cancer Institute and the Salk Institute in San Diego, California on the research which received funding by the Wellcome Trust.

The research focused on E.coli but the protective channel system is common to many pathogens that cause infection and disease.

Professor Booth said: "I started work to understand this system in 1984 so it is tremendously exciting to have made this breakthrough in understanding the molecular workings of these protective channels that are found in several pathogens, many of which are increasingly resistant to traditional antibiotics.

"Our next challenge is to design chemicals that fool the bacterium into locking the channel open all the time, which will then impair its growth, or we could lock it shut so it can't protect itself."

Dr Roosild added: "Discovery of new drugs through the structural analysis of proteins that underlie diseases, including , and are potentially molecular targets for therapeutic intervention, is the primary focus of our research.

"The hope is that these particular studies will eventually lead to the development of new medicines that will cure people with deep seated bacterial infections such as those in intensive care."

Source: University of Aberdeen

Explore further: New system targets germs in donated blood plasma

add to favorites email to friend print save as pdf

Related Stories

Breakthrough could help combat superbugs

Aug 29, 2008

(PhysOrg.com) -- Scientists have worked out a key mechanism that protects bacteria against stress in a major discovery that could lead to new ways of killing superbugs like C. difficile and MRSA.

Protein opens hope of treatment for cystic fibrosis patients

Sep 11, 2008

Scientists have finally identified a direct role for the missing protein that leaves cystic fibrosis patients open to attack from lung-damaging bacteria, the main reason most of them die before their 35th birthday, scientists ...

No hiding place for infecting bacteria

Mar 16, 2009

Scientists in Colorado have discovered a new approach to prevent bacterial infections from taking hold. Writing in the Journal of Medical Microbiology, Dr Quinn Parks and colleagues describe how they used enzymes against produc ...

Breakthrough in the fight against deadly superbug

Jul 17, 2008

(PhysOrg.com) -- The week the government's chief medical officer for England, Sir Liam Donaldson, has announced that the NHS aims to create immunisation against two of the most common superbugs, MRSA and Clostridium ...

Nanotechnology used to probe effectiveness of antibiotics

Feb 04, 2009

A group of researchers led by scientists from the London Centre for Nanotechnology, in collaboration with a University of Queensland researcher, have discovered a way of using tiny nano-probes to help understand how an antibiotic ...

Recommended for you

New system targets germs in donated blood plasma

7 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.